Mitochondrial DNA Copy Number and Leukocyte Telomere Length as Biomarkers in Type 2 Diabetic Patients

NCT05684406 | Unknown

• 1 other identifier: Soh-Med-22-12-19
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

Type 2 diabetes mellitus, which is characterised by a combination of insulin resistance and insufficient insulin secretion is a major contributor to the burden of morbidity and mortality worldwide. the mitochondrial genome contains multiple copies per cell. Because of its close proximity with higher levels of reactive oxidative species, mitochondrial DNA is prone to oxidative stress; which may lead to mitochondrial dysfunction, characterized by lowered oxidative capacity and reduction in energy production. Mitochondrial dysfunction is associated with aging process and can affect cellular functions and thereby results in a variety of human diseases such as cancer, neurodegenerative diseases, cardiovascular diseases, diabetes and metabolic syndrome . Telomere length reflects the cumulative damage from those exposure factors and can be used as a potential indicator of biological aging. Shorter telomere length has been linked to the development of a variety of age-related diseases, such as cancer, cardiovascular disease and diabetes

Conditions

Type 2 Diabetes Mellitus

Outcome Measures

Primary Outcomes (1)

• evaluate the potential of peripheral blood mtDNA-CN as biomarker in type 2 diabetic patients

  evaluate the potential of peripheral blood mtDNA-CN as biomarker in type 2 diabeticients pat patients by Real Time PCR

  within 3 days after collection of samples

Secondary Outcomes (1)

• evaluate the potential of leukocyte telomere length as biomarker in type 2 diabetic patients

  within 3 days after collection of samples

Study Arms (2)

Group I

patients with type 2 diabetes mellitus

Genetic: Genotyping

Group II

apparently healthy controls with no chronic illness of matched age and sex

Genetic: Genotyping

Interventions

Genotyping GENETIC

Genotyping by Real Time PCR

Group I; Group II

Eligibility Criteria

• Age: 15 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with type 2 diabetes mellitus aged from 15 years and above, in internal medicine department of Sohag University Hospital and healthy controls of matched age and sex

You may qualify if:

• This study will include patients who have type 2 diabetes mellitus.

You may not qualify if:

• Patients who have any other chronic illness.
• Patients who have cancer.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Sohag Univversity

Sohag, 82515, Egypt

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

whole blood

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Genotype

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Genetic Phenomena

Study Officials

• Hend Muhammed Naguib

  Sohag University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Hend Muhammed Naguib

CONTACT

01005287752; hendmnaguib@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: assistant lecturer

Study Record Dates

• First Submitted: December 23, 2022
• First Posted: January 13, 2023
• Study Start: January 1, 2023
• Primary Completion: November 1, 2023
• Study Completion: December 1, 2023
• Last Updated: January 13, 2023

Record last verified: 2023-01

Locations

EG (1)